Compare Kinder Morgan Inc (KMI) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Kinder Morgan Inc trades at $33.59 (market cap $74.26B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.65 (market cap $977.37M). The key difference: Kinder Morgan Inc is far larger — about 76× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Kinder Morgan Inc pays a 3.54% dividend while Maravai LifeSciences Holdings Inc. Class A Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 151 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| KMI | MRVI | |
|---|---|---|
Market Cap | $74.26B | $977.37M |
Volume | 12,072,157 | 2,742,564 |
Sector | Energy | Health |
52-Week High | $34.31 | $9.00 |
52-Week Low | $25.84 | $2.83 |
Typical Hold Time | 151 Days | 0 Days |
Enterprise Value | $106.31B | $1.08B |
Dividend Yield | 3.54% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $33.43, up 1.06% with a bullish technical signal and consistent earnings beats. The company demonstrates strong fundamentals with 2025 revenue of $16.94B, net income margin of 19.31%, and robust cash flow generation. Recent news highlights KMI's $6-7B growth pipeline and resilient midstream model amid energy market volatility.
KMI presents a compelling investment case with analyst consensus target of $37.20 (11% upside), strong dividend yield, and exposure to growing natural gas demand. Key risks include energy price volatility, high debt levels ($29.66B long-term), and interest rate sensitivity. The stock offers income and growth potential but requires monitoring of leverage and energy market conditions.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
